Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.
Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.
复制标题
奥洛他定和非索非那定对慢性特发性荨麻疹患者的疗效比较：交叉研究。
DOI：
10.1159/000370312
复制
发表时间：
2015
期刊：
影响因子：
3.1
通讯作者：
Kabashima K
中科院分区：
文献类型：
--
作者：
Tanizaki H;Yamamoto Y;Nakamizo S;Otsuka A;Miyachi Y;Kabashima K
奥洛他定是第二代H1抗组胺药之一，最初在亚洲用于治疗过敏性疾病，现在也在西方国家。尽管有几项试验比较了第二代H1抗组胺药对慢性荨麻疹的疗效，但没有研究直接比较奥洛他定和其他H1抗组胺药对慢性特发性荨麻疹（CIU）患者的临床疗效。在这项研究中，我们首次提出了这个问题，并得出结论，奥洛他定是一个很好的候选治疗慢性荨麻疹。
Olopatadine is one of the second-generation H 1 antihistamines that were used for treating allergic disorders initially in Asia, and now also in Western countries. Whereas several trials compared the efficacy on chronic urticaria among second-generation H 1 antihistamines, no study has directly compared the clinical efficacy between olopatadine and other H 1 antihistamines in patients with chronic idiopathic urticaria (CIU). In this study, we address this issue for the first time and conclude that olopatadine is a good candidate for the treatment of CIU.